Daewoong Pharmaceutical acquires sale right and license of Sandoz’s osteoporosis treatment
Daewoong Pharmaceutical(CEO Jong-Wook Lee) announce the company acquired a Korean sale right and license of ‘Zoledronic Acid Inj 5mg/100ml,’ a osteoporosis treatment, from Novartis and Sandoz Korea.
Under the distribution/promotion agreement with Sandoz Korea, Daewoong Pharmaceutical has exclusi...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.